Lung Cancer Awareness Month with LUNGevity

Lung cancer is by far the leading cause of cancer deaths among both men and women in the United States. This year alone, an estimated 236,740 people will have been diagnosed with lung cancer, and close to 130,180 will lose their lives to this disease. [1]

November is Lung Cancer Awareness Month (LCAM), an opportunity to educate our communities about screening and treatment options, support advocacy groups, and raise greater awareness about the disease. The LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is declaring LCAM “KNOWvember” through their No One Missed campaign - aimed at driving awareness of comprehensive biomarker testing in non-small cell lung cancer (NSCLC). The campaign’s mission is to further educate people about the importance of comprehensive biomarker testing as a critical part of every NSCLC diagnosis and empower patients to discuss access to these tests with their doctor to guide treatment decisions. The campaign connects patients to an active community of survivors and advocates, sharing their biomarker stories as part of the #KnowYourBiomarker initiative.

Exact Sciences partners with the No One Missed campaign to further their vision of a future that ensures there’s No One Missed when it comes to comprehensive biomarker testing in NSCLC. At Exact, we are committed to providing earlier answers and life-saving treatment guidance.

“We are proud to partner with LUNGevity on the No One Missed campaign, as it aligns with the mission and values we have here at Exact Sciences,” said Stephanie Birkey Reffey, director of patient advocacy & alliance relations at Exact Sciences. “The campaign brings together advocacy and biopharma organizations to have a broader discussion on the urgent need for comprehensive biomarker testing in lung cancer. With Exact Sciences’ support, since its launch in 2021, the campaign has reached millions of Americans with greater education about the importance of comprehensive biomarker testing in lung cancer care.”

LUNGevity seeks to improve equity and eliminate health disparities throughout the care continuum. By providing patients with the tools and resources needed to navigate lung cancer care and to amplify their voices, LUNGevity is helping patients receive the care they deserve regardless of their race, ethnicity, gender, sexual identity, age, socioeconomic status, or geographical location. Toward that end, this KNOWvember, LUNGevity is addressing the urgent need for comprehensive biomarker testing among medically underserved audiences in the United States. It’s about inviting those who “know”—patients, advocates, caregivers and more—to share their experiences with biomarker testing and start meaningful conversations with each other and their broader networks.

To learn more about LUNGevity’s No One Missed campaign, visit: https://noonemissed.org/

1. American Cancer Society. Lung Cancer Facts & Figures 2022. Atlanta, GA: American Cancer Society; 2022